The unanimous Supreme Court ruling in the mifepristone case will limit the types of challenges that can be brought against FDA approval decisions and create some stability and predictability for industry.
But the court’s decision not to opine on the case's merits still leaves some health care and legal experts worried about future blows to the agency’s regulatory authority.
The net impact on the FDA and pharma will need to be revisited after the Supreme Court rules on Chevron deference later this month, as well as other pending abortion pill cases in lower courts that touch on federal preemption.

SCOTUS' Mifepristone Decision Sets High Bar For US FDA Suits

Agency Authority Still Faces Risks